• Preclinical data shows that HER-096 promotes functional recovery and regeneration of stressed neurons.

• Results from the Phase 1a first-in-human trial of HER-096 will be presented to the scientific audience for the first time.

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease is announcing two poster presentations at AD/PD 2024 conference, taking place March 5 – 9th in Lisbon, Portugal.

“We look forward to presenting these promising preclinical and clinical data of HER-096 at AD/PD, which is one of the leading conferences in the field of neurodegenerative disorders.” said Dr. Henri Huttunen, CSO of Herantis.

Details of the presentations:

Title: Exploring the multiple mechanisms underlying HER-096 neuroprotection and regeneration.
Authors: Natalia Kulesskaya, Kira M. Holmström and Henri J. Huttunen
Date: March 6th

Conclusions:
A multi-omics approach was employed to uncover the multimodal mechanism underlying the effects of HER-096 on functional recovery in chronic and acute degeneration. Our results suggest that HER-096 promotes functional recovery and regeneration of stressed neurons via multiple complementary ways.

Title: A phase 1a first-in-human clinical trial of HER-096, a subcutaneously administered CDNF-derived peptidomimetic.
Authors: Kira M. Holmström, Katarina Jääskeläinen, Natalia Kulesskaya, Jani Koskinen, Päivi Vuorio, Antti Vuolanto, Marica T. Engström, Mika Scheinin, Charlotte Videbaek, Aleksi Tornio and Henri J. Huttunen
Date: March 6th

Conclusions:

• HER-096 Phase 1a clinical trial met primary and secondary endpoints
• Subcutaneous single dose injections of HER-096 had overall good safety and tolerability profile in young and older healthy subjects
• The pharmacokinetic profile showed fast uptake of HER-096 after subcutaneous injection and demonstrated blood-brain barrier penetration in humans

The posters will be uploaded on Herantis web page (https://herantis.com/scientific-publications/) after the conference. Herantis released the Phase 1a topline data on 25th of October 2023.

About AD/PD 2024:
International conference on Alzheimer and Parkinson’s diseases and related neurological disorders. This conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders. The AD/PD™ Conference has become the main event of the year in the field of neurodegenerative diseases, attracting leading medical and scientific professionals from around the world.

About HER-096:
HER-096 is a brain-penetrating peptidomimetic derived from the active site of human CDNF protein and is developed as a disease-modifying treatment for Parkinson’s disease.

For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

Certified Advisor: UB Corporate Finance Oy, Finland: +358 9 25 380 225

About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com

Forward-looking statements

This release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of operations, the Company’s strategy, objectives, future developments in the markets in which the Company participates or is seeking to participate or anticipated regulatory changes in the markets in which the Company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “should” or “will” or the negative of such terms or other comparable terminology.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The Company’s actual results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis’ strategy, risks and uncertainties associated with the development and/or approval of Herantis’ drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis’ potential market and industry, Herantis’ freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors’ patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors.

In addition, even if Herantis’ historical results of operations, including the Company’s financial condition and liquidity and the development of the industry in which the Company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.